Evaxion Biotech A/S
- EVAX
- NASDAQ
- Biotechnology
- AI-Driven Immunotherapies
$3.33
Today +17.67%Quote Oct 19, 2026, 08:00 PM UTC
+1.83%over the last month
Max drawdown −17.4%From 1-month high −0.3%3 months +10.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Evaxion Biotech A/S
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
46
Founded
2008
Market value
$1.39B
Quote Oct 19
Floor
$3.17
4.8% below price
Resistance
$3.32
Price is above this level
Price vs analyst targets
4 analysts
Lowest target
$9.00Highest target
$16.00
$9.00Highest target
$16.00
- Price $3.33
- Average target $11.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 250% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about EVAXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free